APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Induced Constipation (OIC) Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Opioid Induced Constipation (OIC) Drug Market Outlook and Growth Opportunities 2026

20 December 2025209 pages

Choose your research edition.

Industry ResearchOpioid Induced Constipation (OIC) Drug Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Induced Constipation (OIC) Drug Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Opioid Induced Constipation (OIC) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Induced Constipation (OIC) Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Induced Constipation (OIC) Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Opioid Induced Constipation (OIC) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Opioid Induced Constipation (OIC) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Opioid Induced Constipation (OIC) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Induced Constipation (OIC) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Opioid Induced Constipation (OIC) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Opioid Induced Constipation (OIC) Drug market include Allergan, Bausch Health, C.B. Fleet Company, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, Daiichi Sankyo Co, Ironwood Pharmaceuticals, Mundipharma International Limited and Nektar Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Opioid Induced Constipation (OIC) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid Induced Constipation (OIC) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid Induced Constipation (OIC) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid Induced Constipation (OIC) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioid Induced Constipation (OIC) Drug Segment by Company

Allergan

Bausch Health

C.B. Fleet Company

Cosmo Pharmaceuticals SA

Daewoong Pharmaceutical

Daiichi Sankyo Co

Ironwood Pharmaceuticals

Mundipharma International Limited

Nektar Therapeutics

Ono Pharmaceutical

Progenics Pharmaceuticals

Purdue Pharma

S.L.A. Pharma

Shionogi &

Sucampo Pharmaceuticals

Theravance Biopharma

Pfizer

Takeda Pharmaceutical Company Limited

Opioid Induced Constipation (OIC) Drug Segment by Type

Naldemedine

Lubiprostone

Methyl Naltrexone Bromide

Alvimopan

Other

Opioid Induced Constipation (OIC) Drug Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Opioid Induced Constipation (OIC) Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Opioid Induced Constipation (OIC) Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Opioid Induced Constipation (OIC) Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Opioid Induced Constipation (OIC) Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Opioid Induced Constipation (OIC) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Induced Constipation (OIC) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Induced Constipation (OIC) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Induced Constipation (OIC) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid Induced Constipation (OIC) Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioid Induced Constipation (OIC) Drug industry.

Chapter 3: Detailed analysis of Opioid Induced Constipation (OIC) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Opioid Induced Constipation (OIC) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Opioid Induced Constipation (OIC) Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Opioid Induced Constipation (OIC) Drug Industry Trends Table 2. Opioid Induced Constipation (OIC) Drug Industry Drivers Table 3. Opioid Induced Constipation (OIC) Drug Industry Opportunities and Challenges Table 4. Opioid Induced Constipation (OIC) Drug Industry Restraints Table 5. Global Opioid Induced Constipation (OIC) Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Opioid Induced Constipation (OIC) Drug Revenue Share by Company (2021-2026) Table 7. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Company (2021-2026) Table 9. Global Opioid Induced Constipation (OIC) Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Opioid Induced Constipation (OIC) Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Opioid Induced Constipation (OIC) Drug Key Company Manufacturing Base & Headquarters Table 12. Global Opioid Induced Constipation (OIC) Drug Company, Product Type & Application Table 13. Global Opioid Induced Constipation (OIC) Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioid Induced Constipation (OIC) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Naldemedine Table 18. Significant Companies of Lubiprostone Table 19. Significant Companies of Methyl Naltrexone Bromide Table 20. Significant Companies of Alvimopan Table 21. Significant Companies of Other Table 22. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Type (2021-2026) Table 26. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Type (2027-2032) Table 27. Global Opioid Induced Constipation (OIC) Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Opioid Induced Constipation (OIC) Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Opioid Induced Constipation (OIC) Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Type (2021-2026) Table 31. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Retail Pharmacies Table 33. Significant Companies of Online Pharmacies Table 34. Significant Companies of Hospital Pharmacies Table 35. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Application (2021-2026) Table 39. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Application (2027-2032) Table 40. Global Opioid Induced Constipation (OIC) Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Opioid Induced Constipation (OIC) Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Opioid Induced Constipation (OIC) Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Application (2021-2026) Table 44. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Application (2027-2032) Table 45. Global Opioid Induced Constipation (OIC) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Region (2021-2026) Table 48. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Region (2027-2032) Table 50. Global Opioid Induced Constipation (OIC) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Opioid Induced Constipation (OIC) Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Region (2021-2026) Table 53. Global Opioid Induced Constipation (OIC) Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Region (2027-2032) Table 55. Global Opioid Induced Constipation (OIC) Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Opioid Induced Constipation (OIC) Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Opioid Induced Constipation (OIC) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Opioid Induced Constipation (OIC) Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Country (2021-2026) Table 61. Global Opioid Induced Constipation (OIC) Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Country (2027-2032) Table 63. Global Opioid Induced Constipation (OIC) Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Opioid Induced Constipation (OIC) Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Opioid Induced Constipation (OIC) Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Opioid Induced Constipation (OIC) Drug Sales Value Market Share by Country (2027-2032) Table 67. Allergan Company Information Table 68. Allergan Business Overview Table 69. Allergan Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Allergan Opioid Induced Constipation (OIC) Drug Product Portfolio Table 71. Allergan Recent Development Table 72. Bausch Health Company Information Table 73. Bausch Health Business Overview Table 74. Bausch Health Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Bausch Health Opioid Induced Constipation (OIC) Drug Product Portfolio Table 76. Bausch Health Recent Development Table 77. C.B. Fleet Company Company Information Table 78. C.B. Fleet Company Business Overview Table 79. C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Product Portfolio Table 81. C.B. Fleet Company Recent Development Table 82. Cosmo Pharmaceuticals SA Company Information Table 83. Cosmo Pharmaceuticals SA Business Overview Table 84. Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Product Portfolio Table 86. Cosmo Pharmaceuticals SA Recent Development Table 87. Daewoong Pharmaceutical Company Information Table 88. Daewoong Pharmaceutical Business Overview Table 89. Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio Table 91. Daewoong Pharmaceutical Recent Development Table 92. Daiichi Sankyo Co Company Information Table 93. Daiichi Sankyo Co Business Overview Table 94. Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Product Portfolio Table 96. Daiichi Sankyo Co Recent Development Table 97. Ironwood Pharmaceuticals Company Information Table 98. Ironwood Pharmaceuticals Business Overview Table 99. Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio Table 101. Ironwood Pharmaceuticals Recent Development Table 102. Mundipharma International Limited Company Information Table 103. Mundipharma International Limited Business Overview Table 104. Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Product Portfolio Table 106. Mundipharma International Limited Recent Development Table 107. Nektar Therapeutics Company Information Table 108. Nektar Therapeutics Business Overview Table 109. Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Product Portfolio Table 111. Nektar Therapeutics Recent Development Table 112. Ono Pharmaceutical Company Information Table 113. Ono Pharmaceutical Business Overview Table 114. Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio Table 116. Ono Pharmaceutical Recent Development Table 117. Progenics Pharmaceuticals Company Information Table 118. Progenics Pharmaceuticals Business Overview Table 119. Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio Table 121. Progenics Pharmaceuticals Recent Development Table 122. Purdue Pharma Company Information Table 123. Purdue Pharma Business Overview Table 124. Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Purdue Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio Table 126. Purdue Pharma Recent Development Table 127. S.L.A. Pharma Company Information Table 128. S.L.A. Pharma Business Overview Table 129. S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio Table 131. S.L.A. Pharma Recent Development Table 132. Shionogi & Company Information Table 133. Shionogi & Business Overview Table 134. Shionogi & Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Shionogi & Opioid Induced Constipation (OIC) Drug Product Portfolio Table 136. Shionogi & Recent Development Table 137. Sucampo Pharmaceuticals Company Information Table 138. Sucampo Pharmaceuticals Business Overview Table 139. Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio Table 141. Sucampo Pharmaceuticals Recent Development Table 142. Theravance Biopharma Company Information Table 143. Theravance Biopharma Business Overview Table 144. Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Theravance Biopharma Opioid Induced Constipation (OIC) Drug Product Portfolio Table 146. Theravance Biopharma Recent Development Table 147. Pfizer Company Information Table 148. Pfizer Business Overview Table 149. Pfizer Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Pfizer Opioid Induced Constipation (OIC) Drug Product Portfolio Table 151. Pfizer Recent Development Table 152. Takeda Pharmaceutical Company Limited Company Information Table 153. Takeda Pharmaceutical Company Limited Business Overview Table 154. Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Product Portfolio Table 156. Takeda Pharmaceutical Company Limited Recent Development Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Opioid Induced Constipation (OIC) Drug Distributors List Table 160. Opioid Induced Constipation (OIC) Drug Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Opioid Induced Constipation (OIC) Drug Product Image Figure 2. Global Opioid Induced Constipation (OIC) Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Opioid Induced Constipation (OIC) Drug Sales (2021-2032) & (K Units) Figure 5. Global Opioid Induced Constipation (OIC) Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Opioid Induced Constipation (OIC) Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Naldemedine Image Figure 10. Lubiprostone Image Figure 11. Methyl Naltrexone Bromide Image Figure 12. Alvimopan Image Figure 13. Other Image Figure 14. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Opioid Induced Constipation (OIC) Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Opioid Induced Constipation (OIC) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Type (2021-2032) Figure 20. Retail Pharmacies Image Figure 21. Online Pharmacies Image Figure 22. Hospital Pharmacies Image Figure 23. Global Opioid Induced Constipation (OIC) Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Opioid Induced Constipation (OIC) Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Opioid Induced Constipation (OIC) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Application (2021-2032) Figure 29. Global Opioid Induced Constipation (OIC) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Opioid Induced Constipation (OIC) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Opioid Induced Constipation (OIC) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Opioid Induced Constipation (OIC) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Opioid Induced Constipation (OIC) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Opioid Induced Constipation (OIC) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Opioid Induced Constipation (OIC) Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Opioid Induced Constipation (OIC) Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Naldemedine
  • Lubiprostone
  • Methyl Naltrexone Bromide
  • Alvimopan
  • Other
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Allergan
  • Bausch Health
  • C.B. Fleet Company
  • Cosmo Pharmaceuticals SA
  • Daewoong Pharmaceutical
  • Daiichi Sankyo Co
  • Ironwood Pharmaceuticals
  • Mundipharma International Limited
  • Nektar Therapeutics
  • Ono Pharmaceutical
  • Progenics Pharmaceuticals
  • Purdue Pharma
  • S.L.A. Pharma
  • Shionogi &
  • Sucampo Pharmaceuticals
  • Theravance Biopharma
  • Pfizer
  • Takeda Pharmaceutical Company Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032)
  4. 1.2.2 Global Opioid Induced Constipation (OIC) Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Opioid Induced Constipation (OIC) Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Opioid Induced Constipation (OIC) Drug Market Dynamics
  1. 2.1 Opioid Induced Constipation (OIC) Drug Industry Trends
  2. 2.2 Opioid Induced Constipation (OIC) Drug Industry Drivers
  3. 2.3 Opioid Induced Constipation (OIC) Drug Industry Opportunities and Challenges
  4. 2.4 Opioid Induced Constipation (OIC) Drug Industry Restraints
3 Opioid Induced Constipation (OIC) Drug Market by Company
  1. 3.1 Global Opioid Induced Constipation (OIC) Drug Company Revenue Ranking in 2025
  2. 3.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Company (2021-2026)
  3. 3.3 Global Opioid Induced Constipation (OIC) Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Opioid Induced Constipation (OIC) Drug Average Price by Company (2021-2026)
  5. 3.5 Global Opioid Induced Constipation (OIC) Drug Company Ranking (2024-2026)
  6. 3.6 Global Opioid Induced Constipation (OIC) Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Opioid Induced Constipation (OIC) Drug Company Product Type and Application
  8. 3.8 Global Opioid Induced Constipation (OIC) Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Opioid Induced Constipation (OIC) Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Opioid Induced Constipation (OIC) Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Opioid Induced Constipation (OIC) Drug Market by Type
  1. 4.1 Opioid Induced Constipation (OIC) Drug Type Introduction
  2. 4.1.1 Naldemedine
  3. 4.1.2 Lubiprostone
  4. 4.1.3 Methyl Naltrexone Bromide
  5. 4.1.4 Alvimopan
  6. 4.1.5 Other
  7. 4.2 Global Opioid Induced Constipation (OIC) Drug Sales Volume by Type
  8. 4.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Opioid Induced Constipation (OIC) Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Opioid Induced Constipation (OIC) Drug Sales Value by Type
  12. 4.3.1 Global Opioid Induced Constipation (OIC) Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Opioid Induced Constipation (OIC) Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Type (2021-2032)
5 Opioid Induced Constipation (OIC) Drug Market by Application
  1. 5.1 Opioid Induced Constipation (OIC) Drug Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Opioid Induced Constipation (OIC) Drug Sales Volume by Application
  6. 5.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid Induced Constipation (OIC) Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Opioid Induced Constipation (OIC) Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Opioid Induced Constipation (OIC) Drug Sales Value by Application
  10. 5.3.1 Global Opioid Induced Constipation (OIC) Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioid Induced Constipation (OIC) Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Opioid Induced Constipation (OIC) Drug Sales Value Share by Application (2021-2032)
6 Opioid Induced Constipation (OIC) Drug Regional Sales and Value Analysis
  1. 6.1 Global Opioid Induced Constipation (OIC) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid Induced Constipation (OIC) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Opioid Induced Constipation (OIC) Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Opioid Induced Constipation (OIC) Drug Sales by Region (2027-2032)
  5. 6.3 Global Opioid Induced Constipation (OIC) Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Opioid Induced Constipation (OIC) Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Opioid Induced Constipation (OIC) Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Opioid Induced Constipation (OIC) Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Opioid Induced Constipation (OIC) Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032)
  12. 6.6.2 North America Opioid Induced Constipation (OIC) Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Opioid Induced Constipation (OIC) Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032)
  21. 6.9.2 South America Opioid Induced Constipation (OIC) Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Opioid Induced Constipation (OIC) Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Opioid Induced Constipation (OIC) Drug Sales Value Share by Country, 2025 VS 2032
7 Opioid Induced Constipation (OIC) Drug Country-level Sales and Value Analysis
  1. 7.1 Global Opioid Induced Constipation (OIC) Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Opioid Induced Constipation (OIC) Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Opioid Induced Constipation (OIC) Drug Sales by Country (2027-2032)
  6. 7.4 Global Opioid Induced Constipation (OIC) Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Opioid Induced Constipation (OIC) Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Opioid Induced Constipation (OIC) Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Opioid Induced Constipation (OIC) Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Opioid Induced Constipation (OIC) Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Opioid Induced Constipation (OIC) Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Opioid Induced Constipation (OIC) Drug Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Bausch Health
  8. 8.2.1 Bausch Health Company Information
  9. 8.2.2 Bausch Health Business Overview
  10. 8.2.3 Bausch Health Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bausch Health Opioid Induced Constipation (OIC) Drug Product Portfolio
  12. 8.2.5 Bausch Health Recent Developments
  13. 8.3 C.B. Fleet Company
  14. 8.3.1 C.B. Fleet Company Company Information
  15. 8.3.2 C.B. Fleet Company Business Overview
  16. 8.3.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Product Portfolio
  18. 8.3.5 C.B. Fleet Company Recent Developments
  19. 8.4 Cosmo Pharmaceuticals SA
  20. 8.4.1 Cosmo Pharmaceuticals SA Company Information
  21. 8.4.2 Cosmo Pharmaceuticals SA Business Overview
  22. 8.4.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Product Portfolio
  24. 8.4.5 Cosmo Pharmaceuticals SA Recent Developments
  25. 8.5 Daewoong Pharmaceutical
  26. 8.5.1 Daewoong Pharmaceutical Company Information
  27. 8.5.2 Daewoong Pharmaceutical Business Overview
  28. 8.5.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio
  30. 8.5.5 Daewoong Pharmaceutical Recent Developments
  31. 8.6 Daiichi Sankyo Co
  32. 8.6.1 Daiichi Sankyo Co Company Information
  33. 8.6.2 Daiichi Sankyo Co Business Overview
  34. 8.6.3 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Product Portfolio
  36. 8.6.5 Daiichi Sankyo Co Recent Developments
  37. 8.7 Ironwood Pharmaceuticals
  38. 8.7.1 Ironwood Pharmaceuticals Company Information
  39. 8.7.2 Ironwood Pharmaceuticals Business Overview
  40. 8.7.3 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
  42. 8.7.5 Ironwood Pharmaceuticals Recent Developments
  43. 8.8 Mundipharma International Limited
  44. 8.8.1 Mundipharma International Limited Company Information
  45. 8.8.2 Mundipharma International Limited Business Overview
  46. 8.8.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Product Portfolio
  48. 8.8.5 Mundipharma International Limited Recent Developments
  49. 8.9 Nektar Therapeutics
  50. 8.9.1 Nektar Therapeutics Company Information
  51. 8.9.2 Nektar Therapeutics Business Overview
  52. 8.9.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Product Portfolio
  54. 8.9.5 Nektar Therapeutics Recent Developments
  55. 8.10 Ono Pharmaceutical
  56. 8.10.1 Ono Pharmaceutical Company Information
  57. 8.10.2 Ono Pharmaceutical Business Overview
  58. 8.10.3 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio
  60. 8.10.5 Ono Pharmaceutical Recent Developments
  61. 8.11 Progenics Pharmaceuticals
  62. 8.11.1 Progenics Pharmaceuticals Company Information
  63. 8.11.2 Progenics Pharmaceuticals Business Overview
  64. 8.11.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
  66. 8.11.5 Progenics Pharmaceuticals Recent Developments
  67. 8.12 Purdue Pharma
  68. 8.12.1 Purdue Pharma Company Information
  69. 8.12.2 Purdue Pharma Business Overview
  70. 8.12.3 Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Purdue Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio
  72. 8.12.5 Purdue Pharma Recent Developments
  73. 8.13 S.L.A. Pharma
  74. 8.13.1 S.L.A. Pharma Company Information
  75. 8.13.2 S.L.A. Pharma Business Overview
  76. 8.13.3 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio
  78. 8.13.5 S.L.A. Pharma Recent Developments
  79. 8.14 Shionogi &
  80. 8.14.1 Shionogi & Company Information
  81. 8.14.2 Shionogi & Business Overview
  82. 8.14.3 Shionogi & Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Shionogi & Opioid Induced Constipation (OIC) Drug Product Portfolio
  84. 8.14.5 Shionogi & Recent Developments
  85. 8.15 Sucampo Pharmaceuticals
  86. 8.15.1 Sucampo Pharmaceuticals Company Information
  87. 8.15.2 Sucampo Pharmaceuticals Business Overview
  88. 8.15.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
  90. 8.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 8.16 Theravance Biopharma
  92. 8.16.1 Theravance Biopharma Company Information
  93. 8.16.2 Theravance Biopharma Business Overview
  94. 8.16.3 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Product Portfolio
  96. 8.16.5 Theravance Biopharma Recent Developments
  97. 8.17 Pfizer
  98. 8.17.1 Pfizer Company Information
  99. 8.17.2 Pfizer Business Overview
  100. 8.17.3 Pfizer Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Pfizer Opioid Induced Constipation (OIC) Drug Product Portfolio
  102. 8.17.5 Pfizer Recent Developments
  103. 8.18 Takeda Pharmaceutical Company Limited
  104. 8.18.1 Takeda Pharmaceutical Company Limited Company Information
  105. 8.18.2 Takeda Pharmaceutical Company Limited Business Overview
  106. 8.18.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Product Portfolio
  108. 8.18.5 Takeda Pharmaceutical Company Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioid Induced Constipation (OIC) Drug Value Chain Analysis
  2. 9.1.1 Opioid Induced Constipation (OIC) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioid Induced Constipation (OIC) Drug Sales Mode & Process
  6. 9.2 Opioid Induced Constipation (OIC) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioid Induced Constipation (OIC) Drug Distributors
  9. 9.2.3 Opioid Induced Constipation (OIC) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst